Sputnik V COVID-19 vaccine roll out delayed in Delhi

Fortis Healthcare, which had said it would make Sputnik V available at its Gurgaon and Mohali hospitals from Saturday, also has not started administering the Russian vaccine so far.

Agencies
According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent.
The roll out of Russian COVID-19 vaccine Sputnik V at Indraprastha Apollo and Madhukar Rainbow Children's Hospital in Delhi has been delayed for some days, officials said on Sunday. A spokesperson of Apollo Hospitals said the facility in Delhi will tentatively start administering the two-dose vaccine by June 25.

An official had earlier said the hospital would start giving Sputnik V jabs by June 20.

According to an official of Madhukar Rainbow Children's Hospital, there is a delay on the part of the suppliers.


"We are expecting (roll out) next week," he said.

Fortis Healthcare, which had said it would make Sputnik V available at its Gurgaon and Mohali hospitals from Saturday, also has not started administering the Russian vaccine so far.

"The roll out did not happen on Saturday. We expect there will be some clarity on Monday," an official said.
ADVERTISEMENT

The Centre has fixed the price of the vaccine at Rs 1,145 per dose. The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at Rs 780 per dose, while that of Covaxin is Rs 1,410 per dose.

Russia's Gamaleya National Research Institute of Epidemiology and Microbiology has developed Sputnik V and the Russian Direct Investment Fund (RDIF) is marketing it globally.

Hyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country, has been importing the shots from Russia.

Over a period of time, the vaccine is also going to be manufactured in India.
ADVERTISEMENT

Sputnik V uses two different viruses that cause the common cold (adenovirus) in humans. It employs a different vector for each of the two shots, given 21 days apart.

According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent.
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › News › India › Sputnik V COVID-19 vaccine roll out delayed in Delhi
Text Size:AAA
Success
This article has been saved

*

+